MMS Holdings – an award-winning, data-focused contract research organization (CRO) – has successfully leveraged the support services provided by Medrio, the leading provider of eClinical technology for small to mid-sized pharmaceutical companies, to execute a clinical trial sponsor agreement.
By collaborating to position high-quality CRO services with Medrio’s fast and easy-to-use eClinical products, MMS is actively demonstrating their ability to deliver a fast, flexible, and affordable solution for pharmaceutical sponsors of all sizes. The agreement exemplifies Medrio’s success in providing CROs with not only quality eClinical technology, but also robust support services that help them provide top-tier services to clinical trial sponsors and grow their business.
“Medrio does a lot to ease the process of doing business with our clients,” said Mindy Wolf, Senior Project Manager, MMS. “Their clear, straightforward pricing model makes it easy to get quotes and proposals out quickly. In clinical research, any delay translates to money wasted, so any efficiency in getting proposals issued and to decisions faster is helpful.”
Jim Bademian, Associate Director, Statistical Programming and Data Management at MMS, noted the value of Medrio’s integrated platform, which includes EDC as well as a suite of tablet applications: “We know that if we can offer a client one system provider to help meet all of their business needs, it will be a win for us, for Medrio, and for the client.”
MMS has been a Medrio user for over five years and has leveraged the platform in a multitude of studies. During this time, the company has benefitted significantly from various aspects of Medrio’s functionality, including the ability to:
- Build study databases within two weeks
- Quickly create reports for instant review
- Easily access Medrio’s support team for any technical assistance they need
Their team has found particular success using Medrio in short-term studies. “Medrio is a good solution for sponsors who have very tight timelines,” says Bademian. “MMS can get the database up and running in a very short timeframe.”
“The success of MMS Holdings in facilitating this new sponsor relationship is a clear-cut example of the value of Medrio’s partnerships with our CRO customers,” noted Steve Geffon, Chief Commercial Officer at Medrio. “We’re thrilled to have supported their efforts and are excited to serve them in their upcoming research.”
To learn more about data management with MMS, visit us online.
About MMS Holdings
MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named Most Outstanding Global CRO in the 2019 Biotechnology Awards. For more information, visit http://www.mmsholdings.com or follow MMS on LinkedIn.
Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company’s cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please contact us at our website.